Advertisement

U.S. markets closed

S&P 500
4,320.06
-9.94(-0.23%)
Dow 30
33,963.84
-106.58(-0.31%)
Nasdaq
13,211.81
-12.18(-0.09%)
Russell 2000
1,776.50
-5.32(-0.30%)
Crude Oil
90.33
+0.70(+0.78%)
Gold
1,944.90
+5.30(+0.27%)

Advertisement

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

58.10

-0.71

(-1.21%)

At close: 04:00PM EDT

58.09

-0.01

(-0.02%)

After hours:

06:48PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	58.81
Open	58.77
Bid	58.09 x 800
Ask	58.14 x 1000
Day's Range	57.91 - 59.34
52 Week Range	57.91 - 86.29
Volume	2,265,150
Avg. Volume	1,564,303

Market Cap	13.02B
Beta (5Y Monthly)	0.69
PE Ratio (TTM)	36.54
EPS (TTM)	1.59
Earnings Date	Oct 30, 2023 - Nov 03, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	83.06

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

34% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INCY

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Incyte Corporation
Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Rating
Fair Value
Economic Moat
2 days agoMorningstar

All

Insider Monkey
13 Best Beaten Down Stocks To Buy Now
In this article, we will be taking a look at the 13 best beaten down stocks to buy now. To skip our detailed analysis of the US stock market and recent developments within it, you can go directly to see the 5 Best Beaten Down Stocks To Buy Now. The Two-Day Fed Meeting On September […]
Investor's Business Daily
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.
GuruFocus.com
Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide
An In-depth Analysis of Incyte (INCY)'s Intrinsic Value and Market Position

Advertisement

S&P 5004,320.06-9.94(-0.23%)

Dow 3033,963.84-106.58(-0.31%)

Nasdaq13,211.81-12.18(-0.09%)

Russell 20001,776.50-5.32(-0.30%)

Crude Oil90.33+0.70(+0.78%)

Gold1,944.90+5.30(+0.27%)

Incyte Corporation (INCY)

Chart Events

Performance Outlook

Fair Value

Related Research

13 Best Beaten Down Stocks To Buy Now

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide

S&P 500
4,320.06
-9.94(-0.23%)

Dow 30
33,963.84
-106.58(-0.31%)

Nasdaq
13,211.81
-12.18(-0.09%)

Russell 2000
1,776.50
-5.32(-0.30%)

Crude Oil
90.33
+0.70(+0.78%)

Gold
1,944.90
+5.30(+0.27%)